GlucoTrack (GCTK)
NASDAQ:GCTK
Want to see GCTK full AI Analyst Report?
Top Page
GlucoTrack
(NASDAQ:GCTK)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.48
▼(-75.13% Downside)
Action:Reiterated
Date:05/16/26
The score is primarily constrained by weak financial performance (no meaningful revenue, large losses, heavy cash burn, and negative equity) and a clearly bearish technical trend (below major moving averages with weak momentum). Corporate events add significant uncertainty due to Nasdaq delisting risk, only partly offset by positive regulatory and preclinical progress; valuation provides limited support given the lack of dividend and the interpretability limits of an extremely low P/E.
Positive Factors
IDE submission to FDA (clinical transition)
Submitting an IDE marks a structural shift from preclinical to clinical development in the U.S., enabling generation of pivotal human data required for regulatory approvals. This advances the company down a defined regulatory pathway and materially increases the likelihood of future commercialization if trials succeed.
Negative Factors
No revenue; persistent cash burn
Sustained negative operating and free cash flow with essentially no revenue creates an ongoing funding imperative. Over months, this elevates dilution and financing risk, constrains R&D and commercial investment flexibility, and heightens the chance the company must secure dilutive capital before revenue emerges.
Read all positive and negative factors
Positive Factors
Negative Factors
IDE submission to FDA (clinical transition)
Submitting an IDE marks a structural shift from preclinical to clinical development in the U.S., enabling generation of pivotal human data required for regulatory approvals. This advances the company down a defined regulatory pathway and materially increases the likelihood of future commercialization if trials succeed.
Read all positive factors
GlucoTrack (GCTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.14M
Dividend YieldN/A
Average Volume (3M)2.54M
Price to Earnings (P/E)―
Beta (1Y)3.06
Revenue GrowthN/A
EPS Growth99.39%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-6.31
Shares Outstanding6,259,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit160.39
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GlucoTrack Business Overview & Revenue Model
Company Description
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose mon...
How the Company Makes Money
null...
GlucoTrack Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
24
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.74M | -16.05M | -14.51M | -7.08M | -4.41M | -3.94M |
| Net Income | -16.89M | -19.39M | -22.60M | -7.10M | -4.43M | -4.07M |
Balance Sheet | ||||||
| Total Assets | 4.36M | 7.84M | 5.93M | 4.91M | 2.44M | 6.26M |
| Cash, Cash Equivalents and Short-Term Investments | 3.93M | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M |
| Total Debt | 26.00K | 33.00K | 267.00K | 196.00K | 195.00K | 250.00K |
| Total Liabilities | 5.21M | 5.01M | 18.93M | 1.71M | 1.21M | 1.11M |
| Stockholders Equity | -851.00K | 2.83M | -13.00M | 3.20M | 1.23M | 5.16M |
Cash Flow | ||||||
| Free Cash Flow | -16.44M | -15.34M | -12.59M | -6.56M | -3.73M | -3.77M |
| Operating Cash Flow | -16.35M | -15.24M | -12.49M | -6.56M | -3.73M | -3.77M |
| Investing Cash Flow | -87.00K | -96.00K | -104.00K | 0.00 | 1.00K | -1.00K |
| Financing Cash Flow | 11.24M | 17.04M | 13.74M | 8.73M | 0.00 | 0.00 |
GlucoTrack Technical Analysis
Neutral
1.93
Price Trends
0.74
Negative
1.41
Negative
3.60
Negative
Market Momentum
-0.04
Negative
47.59
Neutral
76.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GCTK, the sentiment is Neutral. The current price of 1.9300000000000002 is above the 20-day moving average (MA) of 0.65, above the 50-day MA of 0.74, and below the 200-day MA of 3.60, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 47.59 is Neutral, neither overbought nor oversold. The STOCH value of 76.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GCTK.
GlucoTrack Risk Analysis
GlucoTrack disclosed 36 risk factors in its most recent earnings report. GlucoTrack reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GlucoTrack Peers Comparison
UnderperformOutperform
Sector (51)
GCTK
GlucoTrack
0.67
-7.58
-91.93%
FEMY
Femasys
0.37
-0.43
-54.00%
WOK
WORK Medical Technology Group LTD
0.11
-8,499.89
-100.00%
GlucoTrack Corporate Events
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk
Negative
May 15, 2026
On May 11, 2026, GlucoTrack received a Nasdaq Staff Determination letter stating that its shares no longer met the $1.00 minimum bid price requirement, prompting Nasdaq staff to move toward delisting the stock from The Nasdaq Capital Market. The c...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GlucoTrack Files IDE for Implantable Glucose Monitor
Positive
May 7, 2026
On May 7, 2026, Glucotrack announced that it has submitted an Investigational Device Exemption application to the U.S. Food and Drug Administration, seeking authorization to begin a U.S. clinical study of its fully implantable continuous blood glu...
Business Operations and StrategyPrivate Placements and Financing
GlucoTrack Executes Debt-for-Equity Exchange and Investor Update
Positive
Apr 30, 2026
On April 29, 2026, Glucotrack, Inc. entered into an exchange agreement with an existing investor to carve out a new $988,000 partitioned promissory note from a previously issued note and then swap that partitioned note for 1,300,000 shares of comm...
Business Operations and StrategyProduct-Related Announcements
GlucoTrack Reports Strong Preclinical Data for Implantable CBGM
Positive
Apr 30, 2026
On April 30, 2026, Glucotrack announced that a peer-reviewed study in The Journal of Diabetes Research demonstrated long-term accuracy and stability of its fully implantable continuous blood glucose monitoring (CBGM) system in an in-vivo ovine mod...
Business Operations and StrategyPrivate Placements and Financing
GlucoTrack Executes Debt-for-Equity Exchange to Reduce Obligations
Positive
Apr 14, 2026
On April 13, 2026, Glucotrack, Inc. signed an Exchange Agreement with an existing investor to carve out a new $600,000 promissory note from a prior $3.6 million note and then swap that new “Partitioned Note” for 895,000 common shares. ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
GlucoTrack Prepares FDA Submission for Implantable CBGM Trial
Positive
Mar 27, 2026
On March 27, 2026, Glucotrack recapped a series of 2024–2025 milestones that have positioned it to submit an Investigational Device Exemption to the U.S. Food and Drug Administration in the second quarter of 2026 for a U.S. clinical trial of...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
GlucoTrack Shareholders Approve Capital Flexibility and Auditor Ratification
Positive
Mar 13, 2026
On March 12, 2026, Glucotrack shareholders approved multiple capital and governance measures at a special meeting that reached quorum with about 44.1% of eligible common shares represented. Investors backed a Nasdaq Stock Issuance (ELOC) Proposal ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.